Keyword: Regeneron Pharmaceuticals
Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.
With drugmakers on the hunt for COVID-19 therapeutic, could one of a range of repurposed meds offer a solution? We run down the latest options.
Through weeks of sleepless nights and conference calls, Regeneron's research team is well positioned to solve COVID-19 with regulators' backing.
With Sanofi and Regeneron testing IL-6 med Kevzara to treat COVID-19, another drug in the class is rolling into testing in an Italian hospital.
Sanofi and Regeron aim to fast track arthritis med Kevzara for use in novel coronavirus patients with an immediate phase 2/3 global clinical program.
Gilead's remdesivir, if effective, could scale up fast, experts said, and antibodies in development, like Regeneron's, might beat vaccines to market.
With drugmakers pushing for a treatment for COVID-19, Regeneron's "innovative" approach could make it the leader of the pack, one analyst wrote.
Regeneron and Sanofi are the latest drugmakers to explore whether an existing medicine might be able to fight the novel coronavirus.
Sanofi and Regeneron's Dupixent could be on its way to €10 billion a year, but pushback from England's cost watchdog in severe asthma won't help.
Several of the industry's top players had a strong performance in the fourth quarter, growing revenues at high single digits. Others? Not so much.